Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis

Amiselimod, a novel sphingosine 1-phosphate receptor-1 modulator, has potent therapeutic efficacy for autoimmune diseases, with low bradycardia risk

(2016) Kunio Sugahara et al.   BRITISH JOURNAL OF PHARMACOLOGY

Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial

(2016) Ludwig Kappos et al.   LANCET NEUROLOGY

Fingolimod in the treatment of relapsing–remitting multiple sclerosis: long-term experience and an update on the clinical evidence

(2016) Bhupendra O. Khatri   Therapeutic Advances in Neurological Disorders

Clinical Characteristics and Circumstances of Death in the Sudden Arrhythmic Death Syndrome

(2014) Greg Mellor et al.   Circulation-Arrhythmia and Electrophysiology

Oral fingolimod (FTY720) in multiple sclerosis: Two-year results of a phase II extension study

(2009) P. O'Connor et al.   NEUROLOGY

Multiple sclerosis

(2008) Alastair Compston et al.   LANCET